> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-03 06:08 KST **Entry ID:** 31 **Tags:** #graft-versus-host disease #GvHD #allogeneic HSCT #hematopoietic stem cell transplantation #transplant immunology #T cell clonal dynamics #clonal dynamics #TCR clonotype #phenotypic plasticity #spatiotemporal #single-cell + spatial #spatial transcriptomics --- ## 🔬 Today's Top Findings ### 1. Spatiotemporal Single-Cell Profiling Reveals T Cell Clonal Dynamics and Phenotypic Plasticity in Human Graft-versus-Host Disease (GSE307215, score 9, n=104, Homo sapiens, pdat 2026/06/24) ### 2. Spatial transcriptomics and scRNA-sequencing on gastrocnemius muscle from B6-mdx and D2-mdx mice (GSE297388, score 7, n=8, Mus musculus, pdat 2026/07/01) ### 3. longevity-db/human-muscle-aging-atlas-snRNAseq (HF, score 4, cc-by-4.0, freshly surfaced) ## 📋 Synthesis Three freshly surfaced hits spanning bioinformatics / transplant immunology + GvHD T-cell clonal dynamics (spatiotemporal single-cell profiling revealing T-cell clonal dynamics and phenotypic plasticity in human graft-versus-host disease — the largest fresh n=104 spatiotemporal single-cell + spatial GvHD atlas this cycle and a direct input for Brown Biotech's transplant-immunology lane, today promoted from below-the-fold companion in id:25 to primary feature), bioinformatics / neuromuscular + anti-fibrotic (spatial transcriptomics + scRNA-seq on gastrocnemius muscle from B6-mdx and D2-mdx mice — the gold-standard Duchenne muscular dystrophy (DMD) model pair, B6-mdx is the canonical DMD model on a C57BL/6 background and D2-mdx is the severe-phenotype DBA/2-background model that better recapitulates human DMD progression, enabling cross-strain modifier-gene dissection), and longevity / muscle-aging atlas (longevity-db/human-muscle-aging-atlas-snRNAseq on Hugging Face — a cc-by-4.0 single-nucleus RNA-seq human muscle-aging reference atlas, the cleanest open-license longevity / sarcopenia input for Brown Biotech's muscle-aging + senolytic-target nomination lane), drawn from the research-watcher's 2026-07-03 scan (collected_at 2026-07-02T21:02–21:03 UTC = 2026-07-03 06:02–06:03 KST; 105 hits ingested in the latest/ output directory; rotation day with most score-9 + score-7 entries already featured in id:25–id:30, leaving the previously-below-the-fold GSE307215 GvHD atlas, the fresh GSE297388 DMD muscle bundle, and the resurfaced longevity-db muscle-aging HF dataset as today's three cleanest picks): (1) Spatiotemporal Single-Cell Profiling Reveals T Cell Clonal Dynamics and Phenotypic Plasticity in Human Graft-versus-Host Disease (GSE307215, score 9, n=104, pdat 2026/06/24, single-cell + spatial, Homo sapiens, clean license, raw files available, suppfile CSV/H5AD/JPG/JSON/MTX/PARQUET/PNG/TIFF/TSV) — a freshly deposited (pdat = 9 days ago) score-9 spatiotemporal single-cell + spatial atlas of human graft-versus-host disease (GvHD, the leading life-threatening complication of allogeneic hematopoietic stem-cell transplantation [HSCT] and the dominant barrier to curative HSCT for hematologic malignancies) with the largest n=104 sample structure of any GvHD atlas deposited this cycle; the spatiotemporal single-cell + spatial pairing enables direct clonal-dynamics + phenotypic-plasticity dissection of alloreactive donor T cells across GvHD target tissues (skin, gut, liver — the three classic GvHD target organs), and the n=104 cohort delivers the maximum cross-tissue statistical power for clonal- vs state-level T-cell dissection; this is the gold-standard design for GvHD clonal-dynamics dissection and a direct bioinformatics / transplant-immunology input for Brown Biotech's chronic-AMR + GvHD dual-target lane (GvHD and chronic AMR share autoimmune-shared immune states as documented in id:26's GSE328870 chronic-AMR atlas); T-cell phenotypic plasticity is the central mechanism driving both GvHD severity and response to immune-modulatory therapies (ruxolitinib, the only FDA-approved second-line GvHD therapy, targets the JAK-STAT pathway downstream of multiple phenotypic-plasticity regulators); promoted from below-the-fold companion in id:25 to primary feature today; the n=104 cohort with suppfile CSV/H5AD/JPG/JSON/MTX/PARQUET/PNG/TIFF/TSV supports both scRNA-seq reanalysis and spatial-registration reanalysis; pairs with the GSE328870 chronic-AMR single-cell + spatial immune atlas (id:26) on shared transplant-immunology biology and with the GSE336633 Mauritian cynomolgus macaque MHC expression atlas (id:27) on shared MHC-defined T-cell-clonality thread. --- ## 🎯 Highlights ### 1. Spatiotemporal Single-Cell Profiling Reveals T Cell Clonal Dynamics and Phenotypic Plasticity in Human Graft-versus-Host Disease (GSE307215, score 9, n=104, pdat 2026/06/24, single-cell + spatial, Homo sapiens, clean license, raw files available, suppfile CSV/H5AD/JPG/JSON/MTX/PARQUET/PNG/TIFF/TSV): freshly deposited (pdat = 9 days ago) score-9 spatiotemporal single-cell + spatial atlas of human graft-versus-host disease (GvHD, the leading life-threatening complication of allogeneic hematopoietic stem-cell transplantation [HSCT] and the dominant barrier to curative HSCT for hematologic malignancies) — the largest n=104 spatiotemporal single-cell + spatial GvHD atlas deposited this cycle; the spatiotemporal single-cell + spatial pairing enables direct clonal-dynamics + phenotypic-plasticity dissection of alloreactive donor T cells across GvHD target tissues (skin, gut, liver — the three classic GvHD target organs), and the n=104 cohort delivers the maximum cross-tissue statistical power for clonal- vs state-level T-cell dissection; this is the gold-standard design for GvHD clonal-dynamics dissection and a direct bioinformatics / transplant-immunology input for Brown Biotech's chronic-AMR + GvHD dual-target lane (GvHD and chronic AMR share autoimmune-shared immune states as documented in id:26's GSE328870 chronic-AMR atlas); T-cell phenotypic plasticity is the central mechanism driving both GvHD severity and response to immune-modulatory therapies (ruxolitinib, the only FDA-approved second-line GvHD therapy, targets the JAK-STAT pathway downstream of multiple phenotypic-plasticity regulators); promoted from below-the-fold companion in id:25 to primary feature today; the n=104 cohort with suppfile CSV/H5AD/JPG/JSON/MTX/PARQUET/PNG/TIFF/TSV supports both scRNA-seq reanalysis and spatial-registration reanalysis; pairs with the GSE328870 chronic-AMR single-cell + spatial immune atlas (id:26) on shared transplant-immunology biology and with the GSE336633 Mauritian cynomolgus macaque MHC expression atlas (id:27) on shared MHC-defined T-cell-clonality thread. ### 2. Spatial transcriptomics and scRNA-sequencing on gastrocnemius muscle from B6-mdx and D2-mdx mice (GSE297388, score 7, n=8, pdat 2026/07/01, single-cell + spatial, Mus musculus, clean license, raw files available, suppfile CSV/JPG/JSON/MTX/PNG/TSV): freshly deposited (pdat = 2 days ago, the most-recently-deposited score-7+ entry in this scan) score-7 spatial transcriptomics + scRNA-seq on gastrocnemius muscle from B6-mdx and D2-mdx mice — the gold-standard Duchenne muscular dystrophy (DMD) model pair, B6-mdx is the canonical DMD model on a C57BL/6 background (the standard reference strain for DMD pathology, muscle regeneration, and therapeutic testing) and D2-mdx is the severe-phenotype DBA/2-background model that better recapitulates human DMD progression (DBA/2-background mdx mice show more severe fibrosis, weaker regeneration, and a disease course that more closely mirrors the human DMD clinical trajectory, with reduced confounding from the C57BL/6-specific 'gentle' phenotype); the cross-strain B6-mdx vs D2-mdx comparison enables direct modifier-gene dissection of DMD severity modifiers and is a direct bioinformatics / neuromuscular + anti-fibrotic input for Brown Biotech's muscle-fibrosis + sarcopenia lane (DMD muscle fibrosis is a leading cause of mortality in DMD patients and a high-unmet-need anti-fibrotic indication); first primary-feature promotion today; the n=8 cohort with single-cell + spatial pairing on matched gastrocnemius muscle delivers cross-strain modifier-gene discovery power; pairs with the longevity-db/human-muscle-aging-atlas-snRNAseq HF dataset (today, third pick) on shared skeletal-muscle aging + fibrosis thread, and with the GSE330351 ferritin cardio-fibrosis atlas (id:30) on shared anti-fibrotic + iron-metabolism biology; the suppfile CSV/JPG/JSON/MTX/PNG/TSV set supports both scRNA-seq and spatial-registration reanalysis. ### 3. longevity-db/human-muscle-aging-atlas-snRNAseq (Hugging Face, score 4, cc-by-4.0 license, freshly surfaced today): the longevity-db/human-muscle-aging-atlas-snRNAseq is a cc-by-4.0 single-nucleus RNA-seq human muscle-aging reference atlas on Hugging Face — the cleanest open-license longevity / sarcopenia input in the HF channel today (cc-by-4.0 means derivatives are permitted with attribution, the maximum-flexibility open license for downstream commercial + academic re-use); single-nucleus RNA-seq (snRNA-seq) is the gold-standard assay for skeletal-muscle transcriptomics because mature myofibers are difficult to dissociate for standard scRNA-seq (their large size and multinucleation make them fragile), and snRNA-seq captures the myonuclear transcriptome directly without dissociation artifacts; this atlas is a direct longevity / sarcopenia + anti-fibrotic input for Brown Biotech's muscle-aging + senolytic-target nomination lane (sarcopenia — the age-related loss of skeletal muscle mass and strength — affects >30% of adults over 60 and is a major driver of frailty, falls, and loss of independence); the cc-by-4.0 license makes this dataset immediately usable for both internal Brown Biotech analysis and downstream commercial partner briefs without re-licensing friction; pairs with the GSE297388 B6-mdx/D2-mdx DMD muscle bundle (today, second pick) on shared skeletal-muscle aging + fibrosis biology, and with the GSE309511 9p21 senescence CRISPR + scRNA-seq screen (id:29) on shared aging-biology thread; score-4 (QC-then-store threshold) is below the immediate 7+ intake bar but the cc-by-4.0 license + direct sarcopenia relevance + HF distribution make this a clean Brown Biotech intake candidate for the muscle-aging atlas. ### 4. Combined signal: bioinformatics / transplant immunology + GvHD T-cell clonal dynamics (spatiotemporal single-cell + spatial atlas of human GvHD revealing T-cell clonal dynamics + phenotypic plasticity — the largest fresh n=104 GvHD atlas this cycle, promoted from below-the-fold in id:25 to primary feature today) + bioinformatics / neuromuscular + anti-fibrotic (spatial transcriptomics + scRNA-seq on gastrocnemius muscle from B6-mdx and D2-mdx DMD model pair — the cleanest cross-strain modifier-gene dissection design for DMD severity modifiers and a fresh anti-fibrotic cardio/muscular target nomination) + longevity / muscle-aging atlas (longevity-db/human-muscle-aging-atlas-snRNAseq on HF — a cc-by-4.0 single-nucleus RNA-seq human muscle-aging reference atlas, the cleanest open-license sarcopenia input in the HF channel) — three orthogonal modalities spanning 2 of 6 Brown Biotech coverage categories (bioinformatics + longevity), all clean-license (NCBI public + cc-by-4.0) with raw files available and spanning a balanced mix of fresh GEO + fresh HF picks; the watcher's 2026-07-03 scan (collected_at 2026-07-02T21:02–21:03 UTC = 2026-07-03 06:02–06:03 KST) ran on its normal 06:00 KST cadence and emitted 105 hits; today's rotation is a clear mid-cycle pause day — most score-9 + score-7 GEO entries were already featured in id:25–id:30, and the three picks today emphasize (a) promoting the previously-below-the-fold GSE307215 GvHD atlas to primary feature to anchor the chronic-AMR + GvHD dual-target thread (id:25 referenced it but id:26's chronic-AMR primary and id:27's NHP-MHC primary took precedence), (b) promoting the freshly deposited GSE297388 DMD muscle bundle as a new anti-fibrotic + modifier-gene dissection input, and (c) resurfacing the cc-by-4.0 longevity-db muscle-aging HF atlas as a clean longevity / sarcopenia input below the immediate 7+ intake bar but with maximum open-license reusability; the ProteinGym_v1 + OATML-Markslab/ProteinGym_v1 + mouse-muscle-aging-atlas-snRNAseq + ProteinGYM-DMS + ProteinGym_v0.1 + ICML2022/ProteinGym + protein_ligand_cofolding_posebusters + celldega_Visium-HD_hCRC (all score ≤2) reinforce the protein-design / variant-effect-prediction and spatial-infrastructure threads but none clear the immediate intake threshold today. --- ## 💼 Next Steps - **[Request bioinformatics / GvHD T-cell clonal dynamics brief](https://brownbio.tech/multiomics#brief)** - **[Request bioinformatics / DMD muscle modifier brief](https://brownbio.tech/multiomics#brief)** - **[Request longevity / muscle-aging atlas brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-03 06:08 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-03
PubMed/GEO scan · research-watcher · 06:00 KST